Smith WB - Search Results

1

Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease.

Ayalon G, Lee SH, Adolfsson O, Foo-Atkins C, Atwal JK, Blendstrup M, Booler H, Bravo J, Brendza R, Brunstein F, Chan R, Chandra P, Couch JA, Datwani A, Demeule B, DiCara D, Erickson R, Ernst JA, Foreman O, He D, Hötzel I, Keeley M, Kwok MCM, Lafrance-Vanasse J, Lin H, Lu Y, Luk W, Manser P, Muhs A, Ngu H, Pfeifer A, Pihlgren M, Rao GK, Scearce-Levie K, Schauer SP, Smith WB, Solanoy H, Teng E, Wildsmith KR, Bumbaca Yadav D, Ying Y, Fuji RN, Kerchner GA. Ayalon G, et al. Among authors: smith wb. Sci Transl Med. 2021 May 12;13(593):eabb2639. doi: 10.1126/scitranslmed.abb2639. Sci Transl Med. 2021. PMID: 33980574 Clinical Trial.

2

JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers.

van der Velden JL, Ye Y, Nolin JD, Hoffman SM, Chapman DG, Lahue KG, Abdalla S, Chen P, Liu Y, Bennett B, Khalil N, Sutherland D, Smith W, Horan G, Assaf M, Horowitz Z, Chopra R, Stevens RM, Palmisano M, Janssen-Heininger YM, Schafer PH. van der Velden JL, et al. Clin Transl Med. 2016 Dec;5(1):36. doi: 10.1186/s40169-016-0117-2. Epub 2016 Sep 2. Clin Transl Med. 2016. PMID: 27590145 Free PMC article.

3

Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.

Smith WB, Dowell JA, Pratt RD. Smith WB, et al. Clin Ther. 2007 Jul;29(7):1368-80. doi: 10.1016/j.clinthera.2007.07.014. Clin Ther. 2007. PMID: 17825688 Clinical Trial.

4

The effect of mild to moderate renal impairment on the pharmacokinetics of the nucleoside analog hepatitis C virus polymerase inhibitor mericitabine.

Haznedar J, Moreira S, Marbury T, Robson R, Smith W, Kulkarni R, Munson ML, Thommes JA, Lemenuel-Diot A, Washington C, Smith P, Chen YC. Haznedar J, et al. Drug Dev Res. 2014 Mar;75(2):107-13. doi: 10.1002/ddr.21166. Epub 2013 Dec 26. Drug Dev Res. 2014. PMID: 24648253 Clinical Trial.

5

Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment.

Xu Y, Izumi R, Nguyen H, Kwan A, Kuo H, Madere J, Slatter JG, Podoll T, Vishwanathan K, Marbury T, Smith W, Preston RA, Sharma S, Ware JA. Xu Y, et al. J Clin Pharmacol. 2022 Jun;62(6):812-822. doi: 10.1002/jcph.2013. Epub 2022 Feb 15. J Clin Pharmacol. 2022. PMID: 34897701 Free PMC article.

6

A growth-differentiation factor 15 receptor agonist in randomized placebo-controlled trials in healthy or obese persons.

Smith WB, Nguyen D, Clough T, Schofield J, Kagan MR, Kompa J, He Y, Maratos-Flier E, Jamontt J, Vong L, Schwartzkopf CD, Layne JD, Usera AR, O'Donnell CJ, Heldwein KA, Streeper RS, Goldfine AB. Smith WB, et al. J Clin Endocrinol Metab. 2024 Aug 16:dgae550. doi: 10.1210/clinem/dgae550. Online ahead of print. J Clin Endocrinol Metab. 2024. PMID: 39148430

7

Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment.

Dowell JA, Marbury TC, Smith WB, Henkel T. Dowell JA, et al. Among authors: smith wb. Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0025322. doi: 10.1128/aac.00253-22. Epub 2022 Aug 3. Antimicrob Agents Chemother. 2022. PMID: 35920662 Free PMC article.

8

Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension.

Smith WB, Marbury TC, Komjathy SF, Sumeray MS, Williams GC, Hu MY, Mould DR. Smith WB, et al. Eur J Clin Pharmacol. 2012 Oct;68(10):1385-94. doi: 10.1007/s00228-012-1260-3. Epub 2012 Mar 29. Eur J Clin Pharmacol. 2012. PMID: 22457015 Free PMC article. Clinical Trial.

9

Effect of renal impairment on the pharmacokinetics of prucalopride: a single- dose open-label Phase I study.

Smith WB, Mannaert E, Verhaeghe T, Kerstens R, Vandeplassche L, Van de Velde V. Smith WB, et al. Drug Des Devel Ther. 2012;6:407-15. doi: 10.2147/DDDT.S36142. Epub 2012 Dec 18. Drug Des Devel Ther. 2012. PMID: 23269861 Free PMC article. Clinical Trial.

10

Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment<sup/>

de Jong J, Skee D, Hellemans P, Jiao J, de Vries R, Swerts D, Lawitz E, Marbury T, Smith W, Sukbuntherng J, Mannaert E. de Jong J, et al. Leuk Lymphoma. 2017 Jan;58(1):185-194. doi: 10.1080/10428194.2016.1189548. Epub 2016 Jun 7. Leuk Lymphoma. 2017. PMID: 27267254 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

332 results

Search Page

Filters